HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) acquired by PERRIGO COMPANY
Context
The acquisition of the High Ridge Brands Oral Care assets by Perrigo signifies a definitive densification of the group’s specialized hygiene division. The strategic rationale for this transaction hinges on a "category-dominance" maneuver, merging the target’s technical operational depth in the branded-value children’s segment with the acquirer’s massive Ranir platform. This structural alignment provides the organization with the scientific talent and trademark hardware necessary to address the increasing consumer shift toward high-quality, cost-effective oral health solutions. By incorporating these market-leading value brands, the organization is now positioned to execute a disruptive innovation strategy that offers retail partners exclusive, branded programs alongside traditional private-label offerings.
By taking control of High Ridge Brands, Perrigo Company continues its expansion strategy. Previously, the group had completed 3 acquisitions, including Geiss Destin & Dunn in 2016.
HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO), which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
The High Ridge Brands Oral Care unit operates as a specialized portfolio of value-oriented personal care assets, primarily focusing on the high-fidelity children’s and specialized hygiene markets. The organization thrives on a philosophy of "accessible hygiene," prioritizing the delivery of innovative, licensed, and branded products that challenge premium national incumbents on both price and shelf-appeal. Its value proposition resides in its ability to capture high-frequency consumer loyalty through iconic brands like Firefly® and REACH®, which utilize technical operational depth in product design to make routine self-care engaging for younger demographics. The entity's strategy centers on a disruptive innovation model, providing retail partners with high-margin alternatives to traditional tier-one brands.
Ent. Value
$100–350M
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (USD)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2020 | AMERICAN SECURITIES | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 03/2020 | LBO FRANCE | DUTSCHER | FRANCE | Medical Consumables |
| 02/2020 | TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 10/2019 | DENTRESSANGLE | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 09/2019 | SAGARD | STERIMED | FRANCE | Medical Consumables |
| 08/2019 | PERMIRA | CAMBREX CORPORATION | UNITED STATES | CDMO |
| 07/2019 | 3I | IONISOS | FRANCE | CDMO |
| 07/2019 | BC PARTNERS | Synthon International | NETHERLANDS | Generics / Labs |
| 07/2019 | PERMIRA | QUOTIENT SCIENCES | UNITED KINGDOM | CDMO |
| 05/2019 | ARDIAN | SINTETICA | SWITZERLAND | Pharma & Biotech |
Other operations with PERRIGO COMPANY
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2021 | PERRIGO COMPANY | HRA PHARMA | FRANCE | Generics / Labs |
| 08/2016 | PERRIGO COMPANY | GEISS DESTIN & DUNN (GDD) | UNITED STATES | B2B Specialized Distribution |
| 07/2015 | PERRIGO COMPANY | NATURWOHL PHARMA (YOKEBE) | GERMANY | Generics / Labs |
| 11/2014 | PERRIGO COMPANY | OMEGA PHARMA | BELGIUM | Generics / Labs |
REFERENCES
Valuation range: EV $100–350M
Revenue range: $100–200M
EV/Revenue range: 1x - 3x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) by PERRIGO COMPANY are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.